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Liver fibrosis is amajor cause ofmorbidity andmortality worldwide due to chronic viral hepatitis and,more recently, from fatty liver
diseases. Activation and proliferation of hepatic stellate cells (HSCs) represent a key aspect of fibrogenesis and are associated with
progressive reduction of HSC apoptosis. Bcl-x, an antiapoptotic member of Bcl-2 gene family, plays a role in apoptosis regulation
in mammalian cells. Through alternative splicing, the Bcl-x gene yields two major protein isoforms with opposing functions,
antiapoptotic Bcl-xL and proapoptotic Bcl-xS. This study aimed to investigate the role of Bcl-x and its alternate splicing in HSC
apoptosis. The results indicated that the expression of Bcl-xL was dramatically higher than Bcl-2 in activated human HSCs. The
relative expression of Bcl-xL over Bcl-xS increased gradually when HSCs were activated in cell culture, which was consistent with
the increase in apoptosis resistance of activated HSCs. Redirection of Bcl-x splicing by an antisense oligonucleotide from the
antiapoptotic isoform to the proapoptotic isoform induced death of HSCs without other apoptosis stimuli. We conclude that Bcl-x
plays a role in regulation of HSC apoptosis and modulation of Bcl-x alternative splicing may become a novel molecular therapy for
liver fibrosis.
1. Introduction
Liver fibrosis represents a pathological response to chronic
liver damage and is associated with inflammation and exces-
sive accumulation of extracellular matrix (ECM) [1, 2]. There
is mounting demand for effective therapies for liver fibrosis
and its end-stage sequela of cirrhosis as they have become
a major source of morbidity and mortality in humans [3].
According to the WHO Global Burden of Disease study for
the years 2000–2012, 1,021,000 people are estimated to have
died from cirrhosis worldwide in 2012, accounting for 1.8%
of total deaths and a 14.5% increase from 2000. An additional
740,000 deaths occur due to liver cancer, which usually arises
from cirrhosis.The prevalence of liver fibrosis is ever increas-
ing in a population faced with precipitously rising obesity
rates and thereby increasing rates of important risk factors
such as nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis [4, 5]. Approved therapies for the treatment of
fibrosis are currently nonexistent, which produces a serious
economic burden for healthcare systems worldwide and
generates enormous demands for new medical therapies to
halt or reverse fibrosis [4, 6, 7].
The excessive accumulation of ECM in liver is a hallmark
of liver fibrosis and hepatic stellate cells (HSCs) are the major
producers of the fibrotic ECM [2]. HSCs are activated in
response to chronic liver injury and develop a myofibroblast-
like phenotype associated with increased proliferation and
collagen synthesis [4]. As activated HSCs are the major
producers of the fibrotic ECM and the most downstream
cellular effectors of liver fibrosis, survival of HSCs can
determine the progress of liver fibrosis and thereby becomes
another hallmark of liver fibrosis [8, 9]. For example, fibrosis
progression was associated with progressive reduction of
HSC apoptosis in patients with chronic HCV [10]. On
the other hand, fibrosis resolution has been demonstrated
through a mechanism of HSC apoptosis in an animal model
[11]. Thus, stimulating apoptosis of HSCs is considered as a
possible effective strategy to achieve liver fibrosis resolution
[6, 9, 12, 13]. Activated human HSCs are resistant to many
proapoptotic stimuli, such as serum deprivation, Fas-ligand,
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Figure 1: Regulation of apoptosis by Bcl-2 family proteins. (a) The apoptotic pathway is initiated when apoptotic stimuli activate BH3-only
members and indirectly induce apoptosis through antagonism of antiapoptotic Bcl-2 proteins. (b) Direction of Bcl-x alternative splicing by
SSO. Alternative splicing of Bcl-x pre-mRNA yields antiapoptotic Bcl-xL and proapoptotic Bcl-xS. SSO redirects the splicing machinery and
results in a simultaneous decrease in production of Bcl-xL and increase in production of Bcl-xS.
and toxic levels of bile acids, and this may result from
increased expression of antiapoptotic protein Bcl-2 [14].
The “apoptotic trigger” in mammalian cells is controlled
by counterbalancing members of the Bcl-2 family, including
the proapoptotic Bax-like proteins, the antiapoptotic Bcl-
2 homologs, and the proapoptotic BH3-only proteins (Fig-
ure 1(a)) [15]. The archetypal member Bcl-2 along with its
closest relatives including Bcl-xL and Mcl-1L is inhibitors
of apoptosis, acting in large part by binding to and thereby
suppressing two proapoptotic triggering proteins (Bax and
Bak); the latter are embedded in the outer mitochondrial
membrane (OMM). When the proapoptotic BH3-only pro-
teins including tBid and Bim relieve them from inhibition by
their antiapoptotic Bcl-2 homologs, Bax and Bak disrupt the
integrity of theOMM, causing the release of proapoptotic sig-
naling proteins such as cytochrome c and thereafter a cascade
of downstream cellular changes associated with the apoptotic
program [15]. The balance of BH3-only and antiapoptotic
Bcl-2 proteins determines whether the cell will commit to
apoptosis. The significance of specific Bcl-2 family members
in apoptosis resistance depends on their relative expression
levels and is specific to cell type. Alternative splicing of some
Bcl-2 family members is a key mechanism for regulation
of these proteins [16]. Through alternative splicing, the Bcl-
x gene yields two major protein isoforms with opposing
functions, antiapoptotic Bcl-xL and proapoptotic Bcl-xS [17,
18].Modulation of the alternative splicing of Bcl-x can change
ability of mammalian cells to resist apoptosis (Figure 1(b))
[16, 19]. Splice-switching oligonucleotide (SSO) is a type
of antisense oligonucleotides that can modulate alternative
splicing by hybridizing to pre-mRNA sequences and blocking
access of various splicing factors [20]. Thus, a SSO can redi-
rect Bcl-x splicing from antiapoptotic Bcl-xL to proapoptotic
Bcl-xS and thereby induce apoptosis of cancer cells [21].
By eliminating an overexpressed prosurvival splice variant
and inducing an apoptotic splice variant simultaneously,
Bcl-x SSO can potentially achieve greater pharmacological
effect than a Bcl-xL inhibitor that can only act on a single
function [20, 22]. Redirection of alternative splicing using
antisense oligonucleotides has achieved initial clinical success
in treating the patients withDuchennemuscular dystrophy in
a phase II clinical trial [23].
The purpose of this study was to investigate the role
of Bcl-x and its alternative splicing in apoptosis of HSCs.
Further, we also aimed to test the feasibility of stimulating
HSC apoptosis using a Bcl-x SSO.
2. Methods
2.1. Materials. The SSOs were 2󸀠-O-Me oligonucleotide with
phosphorothioate linkages and were custom synthesized by
Integrated DNA Technologies, Inc. (Coralville, IA, USA).
The Bcl-x SSO (5󸀠-TGGTTCTTACCCAGCCGCCG-3󸀠) was
targeted to the 5󸀠-splice site of exon II in Bcl-x pre-mRNA
[21, 24] SSO654 (5󸀠-GCTATTACCTTAACCCAG-3󸀠), which
was targeted to intron two of aberrantly spliced 𝛽-globin
and has no effect on Bcl-x pre-mRNA splicing, serving as
negative control. Total RNA of freshly isolated human HSCs
and hepatocytes were obtained from ScienCell Research
Laboratories (San Diego, CA, USA).
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2.2. Cell Culture. Human primary HSCs were purchased
from ScienCell Research Laboratories (San Diego, CA, USA)
and were grown at 37∘C, 5% CO
2
in recommended Stellate
CellMediumprovided by ScienCell according to themethods
reported previously [14, 25, 26]. Consistent with these pre-
vious studies using human primary HSCs, the cells showed
phenotypic features of fully activated HSCs between passages
3 and 7 and thus the cells at passage 7 were used in the
experiments of SSO transfection.
2.3. Real-Time PCR. Total RNA was extracted using an RNA
purification Kit (Thermo Scientific), and cDNA was synthe-
sized from total RNA using an Enhanced Avian RT First
Strand Synthesis Kit (Sigma-Aldrich, St. Louis, MO, USA).
Real-time PCR reactions were performed on an ABI Prism
7900 system (Applied Biosystems). Predesigned TaqMan
primer and probe sets were used for quantification of Bcl-xL
and Bcl-xS (Life Technologies Product IDs Hs00236329 m1
and Hs00169141 m1, resp.). The probes span the boundary of
exons II and III of Bcl-xL and Bcl-xS, respectively. Because
exon II in Bcl-xL has extra 138 bp fragment compared to
that of Bcl-xS [27], the primers and probes only detect the
corresponding splice variants of Bcl-x gene. TaqMan human
𝛽-actin endogenous control (Applied Biosystems) was used
for quantification of 𝛽-actin in each sample and served as an
internal control. The target gene expression levels of samples
were calculated with the Comparative CT Method (ΔΔCT
Method) and were expressed as fold changes over controls.
2.4. Bcl-x Splicing by SSO. Transfection of human HSC
was performed using the Amaxa nucleofection technology
according to a method reported previously [28]. Briefly, 1
million ofHSCswere nucleofected inT solution of theAmaxa
cell optimization kit plus SSOs (0.125–1 nmol) using the U-25
program. The transfected cells were immediately transferred
into 6-well plates containing prewarmed culture medium.
One day after transfection, total RNA was isolated using
TRIZOL reagent (Life Technologies, USA). Relative mRNA
expression levels of Bcl-xL and Bcl-xS were analyzed by gel
electrophoresis. For gel electrophoresis, the PCR products
(Bcl-xL 351 bp and Bcl-xS 162 bp) were separated on 1.7% gels
and bands were visualized and quantified on a Molecular
Imager Gel Doc XR System (Bio-Rad, Hercules, CA).
The ratio of Bcl-xS/Bcl-xL was determined by dividing the
intensity of the 162 bp band by the intensity of the 351 bp band.
2.5. Evaluation of Cytotoxicity and Apoptosis. The cytotoxi-
city of the SSOs was evaluated using Alamar Blue assay. In
brief, human HSCs transfected with Mock SSO and Bcl-x
specific SSO were seeded into 96-well plates at the density of
5,000 cells/well and the cells were further incubated for 72 h.
Alamar Blue reagent was added and incubated for 2 h. The
plate was read in FLUOstar Omega microplate reader (BMG
LabTech,Cary,NC,USA) set at 540 nmexcitationwavelength
and 590 nm emission wavelength.
To evaluate HSC apoptosis, human HSCs were seeded
into 24-well plates at a density of 50,000 cells/well after
transfection with the SSOs using Amaxa. After 24 h, 48 h,
and 72 h, cells were harvested and amitochondrialmembrane
potential/annexin V apoptosis kit (Life Technologies, USA)
was used to identify apoptotic cells according to the manu-
facturer’smanual. Apoptosis wasmeasured by flow cytometry
using a LSRII cell analyzer (Becton-Dickenson, San Jose, CA,
USA).
For confocal fluorescence microscopy observation, the
cells were seeded in Lab-Tek 8 Chambered cover glasses
(Nalge Nunc) at a density of 50,000 cells/well after Amaxa
transfection. After 48 h, cell nuclei were labeled by incubation
with 10 𝜇M of DRAQ5 (BioStatus, UK) for 20min at room
temperature. Cells were then imaged by a laser scanning
confocal microscopy (Olympus FV1000 MPE). Doses of
Mock SSO and Bcl-x specific SSOused in the apoptosis assays
were 0.5 nmol.
2.6. Data Analysis. Data are expressed as mean ± SD from
three measurements unless otherwise noted. Statistical sig-
nificance was evaluated using 𝑡-test for two-sample com-
parison or ANOVA followed by Dunnett’s test for multiple
comparisons. The data were analyzed with GraphPad Prism
5 (GraphPad Software, Inc., La Jolla, CA, USA).
3. Results
3.1. Increased mRNA Expression Ratio of Bcl-x
𝐿
and Bcl-x
𝑆
in Activated Human HSCs. Total RNAs of HSCs in different
passages were collected and subjected to real-time PCR
analysis. As shown in Figure 2(a), the gene expression of
Bcl-xL was 83-fold higher than Bcl-2 in activated human
HSCs (passage 7). The results also showed that the relative
expression ratio of Bcl-xL and Bcl-xS increased in later
passages, from 18 at passage 1 to 65 at passage 7 (Figure 2(b)).
Further, the ratio of Bcl-xL andBcl-xS of freshly isolate human
hepatocytes was significantly lower than that of activated
HSCs (passage 7) (Figure 2(b)).
3.2. Bcl-x Splicing Shift in SSO Transfected Human HSCs.
Human HSCs were transfected with increasing amounts of
Bcl-x SSO, which targeted the downstream alternative 5󸀠-
splice site in Bcl-x pre-mRNA. This SSO could block the
targeted splice site and induce a shift in the splicing pathway
from Bcl-xL to Bcl-xS mRNA [21]. Total cell RNA 24 h after
treatment was subjected to RT-PCR analysis. It is shown in
Figure 3 that Bcl-x SSO treatment led to a dose-dependent
shift in splicing of Bcl-x pre-mRNA from Bcl-xL to Bcl-xS. At
the highest dose of 1 nmol, there was over a 96% shift from
Bcl-xL to Bcl-xS isoform. By contrast, there was no shift in
Bcl-x pre-mRNA splicing in the cells treatedwith the negative
control SSO654 even at the highest dose.
3.3. Cytotoxicity Induced by SSO Treatment. From Figure 3,
we confirmed that shifting splicing of Bcl-x pre-mRNA led
to simultaneous downregulation of antiapoptotic Bcl-xL and
upregulation of proapoptotic Bcl-xS. To evaluate the effect
of Bcl-x SSO on cell survival, an Alamar Blue assay was
performed 72 h after Amaxa transfection of SSOs. As shown
in Figure 4, the Bcl-x specific SSO dose-dependently induced
cytotoxicity in human HSCs. Using the same transfection
method, the control SSO654 did not cause cytotoxicity even
at high dose.
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Figure 2: Gene expression of Bcl-xS and Bcl-xL in human HSCs. Real-time PCR analysis of RNA extracted from human HSCs of different
passages. (a)The gene expression of Bcl-2, Bcl-xL, and Bcl-xS was compared in activated human HSCs (passage 7). (b)The relative expression
ratio of Bcl-xL and Bcl-xS was compared in human hepatocytes and human HSCs at different passages.
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Figure 3: SSO induced Bcl-x splice-switching in human HSCs. RT-
PCR analysis of Bcl-x mRNA from cells transfected with control
and Bcl-x SSO was performed 24 h after transfection.The Bcl-x SSO
dose-dependently induced switching of Bcl-x mRNA splicing from
antiapoptotic Bcl-xL to proapoptotic Bcl-xS.
3.4. Apoptosis of Human HSCs Caused by Bcl-x SSO Trans-
fection. To determine if the decreased cell viability observed
in Figure 4 was caused by HSC apoptosis, flow cytometry
was used to detect the mitochondrial membrane potential
and the expression of phosphatidylserine in the treatedHSCs.
After humanHSCs were transfected with 0.5 nmol SSO using
an Amaxa machine, apoptosis of these cells was determined
by counting the relative amount of annexin V-FITC-positive
and MitoTracker Red-negative cells. Apoptotic cells show
higher levels of green fluorescence and lower red fluorescence
than healthy cells. As shown in Figure 5(a), Bcl-x specific
SSO time-dependently induced apoptosis in human HSCs.
At 24 h after SSO transfection, the apoptotic cells were 21%
of the total cells. The percentage increased to 53% and 75%
at 48 h and 72 h, respectively. In addition, we observed the
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Figure 4: Bcl-x SSO dose-dependently induced cytotoxicity in
HSCs. Human HSCs were transfected with Mock SSO or Bcl-x
SSO using an Amaxa machine. Then cells were seeded into 96-well
plates at the density of 5000 cells/well. After incubation of 72 hours,
Alamar Blue reagent was added and incubated for another 2 hours.
The plate was then read for fluorescence value using a microplate
reader. Bcl-x SSO showed a dose-dependent cytotoxicity. Data are
expressed as mean ± SD (𝑛 = 3).
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Figure 5: Bcl-x SSO treatment induced apoptosis in HSCs. (a) The cells after Amaxa transfection of SSOs (0.5 nmol) for 48 h were subjected
to flow cytometry. The apoptosis kit includes a red dye to indicate mitochondrial membrane potential and a FITC-conjugated annexin V.
Cells in Q4 area indicate apoptotic cells, show high level of green fluorescence, and decreased red fluorescence. Bcl-x SSO treatment evidently
induced apoptosis. (b) Time-course assay of flow cytometry. Bcl-x SSO treatment induced a significant time-dependent apoptosis. (c) Staining
for DNA was performed in HSCs 24 h after SSO treatment.The nuclear changes including condensation and fragmentation indicate classical
apoptosis.
nuclear changes through confocal microscope. As shown in
Figure 5(c), one transfection of 0.5 nmol Bcl-x SSO induced
unclear condensation and fragmentation in human HSCs,
further supporting the apoptosismechanismbyBcl-x SSO. By
contrast, therewas no change in cells treatedwith the negative
control SSO654 at the same dose.These results indicated that
the death of HSCs by SSO transfection was through Bcl-x
SSO-induced apoptosis.
4. Discussion
Stimulating apoptosis of HSCs has been considered as a
necessary step to achieve liver fibrosis resolution [6, 12, 13].
Thus, elucidation of the mechanisms for HSC apoptosis and
identification of the key players in this process can lead to
discovery of new antifibrotic targets and to development of
novel therapeutic strategies. The Bcl-2 gene family plays the
dominant role in regulation of apoptosis of mammalian cells
[29]. Bcl-2, the archetypal member of this gene family, has
been indicated to play an important role in HSC apoptosis
[2]. However, there are other two important antiapoptotic
members in this gene family, Bcl-x and Mcl-1, and they play
important roles in some cell types and diseases [29]. The
significance of individual Bcl-2 family members in apoptosis
resistance depends on their relative expression levels and
is specific to cell type. For example, it has been indicated
that hematopoietic cancers are dependent upon Bcl-2 for
survival or resistance to stress, whereas epithelial cancers
rely on Bcl-xL for chemoresistance [30, 31]. In this study,
we first evaluated the role of Bcl-x in apoptosis of HSCs
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by quantifying mRNA expression levels of Bcl-2 and Bcl-x
in activated HSCs. The results indicated that expression of
Bcl-x is over 83-fold greater than Bcl-2, indicating that Bcl-
x may play an important role in HSC apoptosis regulation.
Alternative splicing of Bcl-x is an important regulation
mechanism.Thus, we measured the relative expression levels
of the two splice variants, Bcl-xL and Bcl-xS, during passaging
of primary culture human HSCs, a process mimicking HSC
activation [32]. We observed that the ratio of Bcl-xL over Bcl-
xS increased from 18 at passage 1 to 65 at passage 7, indicating
an increase in antiapoptotic Bcl-xL expression as well as a
decrease in proapoptotic Bcl-xS expression. The change of
the ratio of these two members with opposite functions in
apoptosis is correlated with the progress of antiapoptosis
of HSCs, indicating it may contribute to the resistance to
apoptosis of HSCs.
Using antisense to switching alternative splicing is a
unique strategy tomodulate gene expression and function. By
eliminating an overexpressed prosurvival splice variant and
inducing an apoptotic splice variant simultaneously, a Bcl-x
SSO can potentially achieve greater pharmacological effect
than classic antisense or siRNA ONs that can only act on a
single function [20, 22]. The results of this study supported
this notion. Our data indicated that Bcl-x SSO treatment
could directly cause cytotoxicity in human HSCs without
other proapoptotic stimuli. By contrast, Bcl-2 silencing by
RNA interference could not induce prominent apoptosis
[14]. Cells became sensitive only when they were treated
with Bcl-2 siRNA and other proapoptotic stimuli such as
TNF𝛼 together [14]. Therefore, the dual functional Bcl-x
SSO may have advantage over single functional siRNA. As
redirection of alternative splicing using SSO has achieved
initial clinical success in treating patients with Duchenne
muscular dystrophy [23], this study may lead to a novel
molecular therapy for liver fibrosis. Further, the effective
stimulation of apoptosis by Bcl-x SSO supported that Bcl-
x and its alternate splicing play an important role in HSC
apoptosis.
The strategy of stimulation of HSC apoptosis is clini-
cally feasible for treating liver fibrosis only if the apoptosis
modulation is specific to HSCs, as hepatocyte death leads to
impaired liver function and even exacerbates liver fibrosis.
Previous studies have indicated that Bcl-x SSO only causes
apoptosis in cells with high expression of Bcl-xL while cells
with low levels of Bcl-xL resisted the treatment [33]. Thus,
we also measured Bcl-x RNA levels in hepatocytes. Its level is
lower than activated HSCs (Figure 1(b)), and thus Bcl-x SSO
may not cause apoptosis in hepatocytes. This notion may be
supported by an animal study using liposomal delivery of Bcl-
x SSO [21]. Liposomal formulation is known to accumulate
nonspecifically in the liver, largely into the hepatocytes, due to
the fenestrated vasculature [34]. However, liposomal delivery
of Bcl-x SSO did not cause liver toxicity, supporting the
idea that the hepatocytes may tolerate Bcl-x SSO due to low
expression of Bcl-xL [21]. To further enhance the specificity of
this strategy, Bcl-x SSO can be targeted to HSCs in vivo using
targeted delivery systems such as M6P modified system [35].
Specific delivery of the therapeutic entity toHSCs can provide
a second safeguard against possible side-effects of Bcl-x SSO
in the hepatocytes [36, 37].
In conclusion, the results in this study support that
modulating Bcl-x gene alternative splicing by antisense
oligonucleotides causes HSC apoptosis and thereby may lead
to a novel molecule therapy of liver fibrosis.
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